Synthetic Self-Assembling ADDomer Scaffold for Next-generation Biotherapeutics

In this project, we will use ADDomer, a versatile, designer antigen-presenting platform we developed. ADDomer originates from a single component of Adenovirus, the penton base protein. Engineered penton base proteins spontaneously form exceptionally stable synthetic virus-like particles in vitro, which are highly soluble and safe as they contain no genetic material. This innovative ADDomer scaffold is uniquely suited to display on a single particle hundreds of pathogenic epitopes and protein domains which are inserted into flexible, variable loops present on the ADDomer surface. In the project here proposed, we will combine expertise in synthetic biology and biodesign with protein engineering and cryo-electron microscopy to achieve a step-change in the potency of the ADDomer technology and create a uniquely powerful ADDoer-based vaccine prototype to combat coronavirus inculding SARS-CoV-2. Moreover, we will establish a versatile platform to enable rapid adaptation if new and currently unknown coronavirus threats arise (SARS-CoV-X). For translation to market, we will work with our industrial partner Imophoron Ltd, an award-winning Bristol start-up developing ADDomer as a next-generation vaccine platform technology. Building on this powerful synergy, we will utilize a range of biochemical, biophysical, engineering and marketing approaches to design, create, characterize, produce and roll-out highly effective next-generation ADDomer-based therapeutics to combat human infectious disease.